Trial intelligence / Profile preview

OPTIMUM

2016-002670-12Phase 2Unknown

Sponsor: University of Leeds
Start: Feb 2017
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, single-arm trial of daratumumab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide in multiple myeloma (MM) and plasma cell leukaemia (PCL), sponsored by University of Leeds. Primary endpoint: Progression-free survival at 18 months post-registration. Status: unknown.

Drugs

daratumumabbortezomiblenalidomidedexamethasonecyclophosphamide

Conditions

multiple myeloma (MM)plasma cell leukaemia (PCL)

Beyond the preview

Go deeper on 2016-002670-12.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2016-002670-12.